Literature DB >> 10595361

Use of minimally modified antisense oligonucleotides for specific inhibition of gene expression.

E Uhlmann1, A Peyman, A Ryte, A Schmidt, E Buddecke.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10595361     DOI： 10.1016/s0076-6879(00)13017-4

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN： 0076-6879            Impact factor:   1.600


× No keyword cloud information.
  10 in total

1.  Propynyl groups in duplex DNA: stability of base pairs incorporating 7-substituted 8-aza-7-deazapurines or 5-substituted pyrimidines.

Authors:  Junlin He; Frank Seela
Journal:  Nucleic Acids Res       Date:  2002-12-15       Impact factor: 16.971

2.  Synthetic antisense oligodeoxynucleotides to transiently suppress different nucleus- and chloroplast-encoded proteins of higher plant chloroplasts.

Authors:  Emine Dinç; Szilvia Z Tóth; Gert Schansker; Ferhan Ayaydin; László Kovács; Dénes Dudits; Gyozo Garab; Sándor Bottka
Journal:  Plant Physiol       Date:  2011-10-06       Impact factor: 8.340

3.  First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy.

Authors:  Malabika Sen; Sufi M Thomas; Seungwon Kim; Joanne I Yeh; Robert L Ferris; Jonas T Johnson; Umamaheswar Duvvuri; Jessica Lee; Nivedita Sahu; Sonali Joyce; Maria L Freilino; Haibin Shi; Changyou Li; Danith Ly; Srinivas Rapireddy; Jonathan P Etter; Pui-Kai Li; Lin Wang; Simion Chiosea; Raja R Seethala; William E Gooding; Xiaomin Chen; Naftali Kaminski; Kusum Pandit; Daniel E Johnson; Jennifer R Grandis
Journal:  Cancer Discov       Date:  2012-06-20       Impact factor: 39.397

4.  Quantitative PCR analysis of DNA aptamer pharmacokinetics in mice.

Authors:  Katherine Perschbacher; John A Smestad; Justin P Peters; Miranda M Standiford; Aleksandar Denic; Bharath Wootla; Arthur E Warrington; Moses Rodriguez; L James Maher
Journal:  Nucleic Acid Ther       Date:  2014-12-23       Impact factor: 5.486

5.  Oxetane modified, conformationally constrained, antisense oligodeoxyribonucleotides function efficiently as gene silencing molecules.

Authors:  J B Opalinska; A Kalota; Lida K Gifford; Ponzy Lu; Kuang-Yu Jen; P I Pradeepkumar; J Barman; T K Kim; C R Swider; J Chattopadhyaya; A M Gewirtz
Journal:  Nucleic Acids Res       Date:  2004-10-28       Impact factor: 16.971

6.  Pharmacokinetics and biodistribution of novel aptamer compositions.

Authors:  Judith M Healy; Scott D Lewis; Markus Kurz; Ryan M Boomer; Kristin M Thompson; Charles Wilson; Thomas G McCauley
Journal:  Pharm Res       Date:  2004-12       Impact factor: 4.200

7.  Transcription factor decoy oligonucleotides modified with locked nucleic acids: an in vitro study to reconcile biostability with binding affinity.

Authors:  Rita Crinelli; Marzia Bianchi; Lucia Gentilini; Linda Palma; Mads D Sørensen; Torsten Bryld; Ravindra B Babu; Khalil Arar; Jesper Wengel; Mauro Magnani
Journal:  Nucleic Acids Res       Date:  2004-03-29       Impact factor: 16.971

Review 8.  Aptamers as both drugs and drug-carriers.

Authors:  Md Ashrafuzzaman
Journal:  Biomed Res Int       Date:  2014-09-11       Impact factor: 3.411

Review 9.  Nucleic Acid Ligands With Protein-like Side Chains: Modified Aptamers and Their Use as Diagnostic and Therapeutic Agents.

Authors:  John C Rohloff; Amy D Gelinas; Thale C Jarvis; Urs A Ochsner; Daniel J Schneider; Larry Gold; Nebojsa Janjic
Journal:  Mol Ther Nucleic Acids       Date:  2014-10-07       Impact factor: 10.183

Review 10.  Aptamers as therapeutics.

Authors:  Anthony D Keefe; Supriya Pai; Andrew Ellington
Journal:  Nat Rev Drug Discov       Date:  2010-07       Impact factor: 84.694
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.